Disease-modifying treatment (DMT) modelling tool launched to unpick the true cost of MS care
A new tool has been launched which models the true financial and workforce resources needed to safely provide disease-modifying therapies (DMTs) to people living with multiple sclerosis (MS). DMTs are an effective means of treating relapsing-remitting MS, the most common form of the condition, reducing the frequency of relapses and the build-up of lesions in […]
Introducing our newest staff member – and the exciting project he leads
The Neurology Academy continues to expand as our work broadens, and we are pleased to welcome a new member of our team, Jamie McGregor. Jamie, whose background is predominantly in law, joins us as Head of Policy, Intelligence and External Affairs. He will be heading up our work in response to the new multiple sclerosis […]
Debate on the NHS England algorithm for MS treatment by disease-modifying drugs
The Neurology Academy hosted a debate at the ABN conference this year to discuss the newly proposed NHS England algorithm for using disease-modifying treatments (DMTs) to manage multiple sclerosis (MS). We interviewed a number of key people at the debate on 9th May to help get a clearer and fuller picture of what this algorithm […]
QuDoS-MS deadline approaching fast – calling all innovators in MS!
The deadline for submitting entries for this year’s Quality in the Delivery of Services in Multiple Sclerosis (QuDoS-MS) recognition programme, organised by the MS Trust and pharmaphorum is Monday 4 September at 5pm.
A carer’s perspective on MS
John is 43 and lives with his wife Sarah, 38, and their two children in South Yorkshire. He told us about Sarah’s MS and what it’s like to be a carer.
“My MS nurse is always my first port of call”
Chris is 30 years old and has relapsing-remitting multiple sclerosis (MS). He lives in Cornwall with his wife and their young child. This MS Awareness Week he told us about his diagnosis and journey with MS so far, and why his MS specialist nurse is so important…
